- Home
- NGVC vs MBX Comparison
NGVC vs MBX Comparison
Compare NGVC & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGVC
- MBX
- Stock Information
- Founded
- NGVC 1955
- MBX 36
- Country
- NGVC United States
- MBX United States
- Employees
- NGVC N/A
- MBX N/A
- Industry
- NGVC Food Chains
- MBX
- Sector
- NGVC Consumer Staples
- MBX
- Exchange
- NGVC Nasdaq
- MBX NYSE
- Market Cap
- NGVC 770.2M
- MBX 762.6M
- IPO Year
- NGVC 2012
- MBX 2024
- Fundamental
- Price
- NGVC $34.79
- MBX $16.24
- Analyst Decision
- NGVC
- MBX Strong Buy
- Analyst Count
- NGVC 0
- MBX 4
- Target Price
- NGVC N/A
- MBX $37.25
- AVG Volume (30 Days)
- NGVC 86.7K
- MBX 97.5K
- Earning Date
- NGVC 11-21-2024
- MBX 11-07-2024
- Dividend Yield
- NGVC 1.15%
- MBX N/A
- EPS Growth
- NGVC 55.98
- MBX N/A
- EPS
- NGVC 1.34
- MBX N/A
- Revenue
- NGVC $1,213,999,000.00
- MBX N/A
- Revenue This Year
- NGVC $6.26
- MBX N/A
- Revenue Next Year
- NGVC $3.80
- MBX N/A
- P/E Ratio
- NGVC $25.71
- MBX N/A
- Revenue Growth
- NGVC 8.42
- MBX N/A
- 52 Week Low
- NGVC $14.31
- MBX $15.31
- 52 Week High
- NGVC $35.00
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- NGVC 75.54
- MBX N/A
- Support Level
- NGVC $32.46
- MBX N/A
- Resistance Level
- NGVC $33.88
- MBX N/A
- Average True Range (ATR)
- NGVC 1.31
- MBX 0.00
- MACD
- NGVC 0.27
- MBX 0.00
- Stochastic Oscillator
- NGVC 97.46
- MBX 0.00
About NGVC Natural Grocers by Vitamin Cottage Inc.
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.